CN110100788A - 基于基因操作策略构建疾病模型的方法和应用 - Google Patents
基于基因操作策略构建疾病模型的方法和应用 Download PDFInfo
- Publication number
- CN110100788A CN110100788A CN201910397466.2A CN201910397466A CN110100788A CN 110100788 A CN110100788 A CN 110100788A CN 201910397466 A CN201910397466 A CN 201910397466A CN 110100788 A CN110100788 A CN 110100788A
- Authority
- CN
- China
- Prior art keywords
- gene
- disease
- emc3
- disease model
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 116
- 238000000034 method Methods 0.000 title claims abstract description 62
- 201000010099 disease Diseases 0.000 title claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 49
- 101150016904 EMC3 gene Proteins 0.000 claims abstract description 68
- 208000007135 Retinal Neovascularization Diseases 0.000 claims abstract description 54
- 210000000449 purkinje cell Anatomy 0.000 claims abstract description 40
- 206010008025 Cerebellar ataxia Diseases 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000010171 animal model Methods 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 34
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 32
- 238000005516 engineering process Methods 0.000 claims description 23
- 210000001638 cerebellum Anatomy 0.000 claims description 22
- 238000011160 research Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 229960001603 tamoxifen Drugs 0.000 claims description 16
- 230000002207 retinal effect Effects 0.000 claims description 15
- 238000003209 gene knockout Methods 0.000 claims description 14
- 230000007246 mechanism Effects 0.000 claims description 14
- 108091033409 CRISPR Proteins 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 9
- 210000002889 endothelial cell Anatomy 0.000 claims description 9
- 230000002792 vascular Effects 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 7
- 238000010362 genome editing Methods 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 238000010354 CRISPR gene editing Methods 0.000 claims description 6
- 230000005021 gait Effects 0.000 claims description 6
- 239000007928 intraperitoneal injection Substances 0.000 claims description 6
- 210000003141 lower extremity Anatomy 0.000 claims description 6
- 230000006459 vascular development Effects 0.000 claims description 6
- 230000006866 deterioration Effects 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 239000002344 surface layer Substances 0.000 claims description 4
- 206010040799 Skin atrophy Diseases 0.000 claims description 3
- 210000003038 endothelium Anatomy 0.000 claims description 3
- 239000002052 molecular layer Substances 0.000 claims description 3
- 238000010459 TALEN Methods 0.000 claims description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 64
- 210000001525 retina Anatomy 0.000 description 26
- 238000011813 knockout mouse model Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 229940000406 drug candidate Drugs 0.000 description 13
- 210000005252 bulbus oculi Anatomy 0.000 description 12
- 210000001210 retinal vessel Anatomy 0.000 description 12
- 206010003591 Ataxia Diseases 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000004043 dyeing Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 206010010947 Coordination abnormal Diseases 0.000 description 7
- 208000016290 incoordination Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 108020003519 protein disulfide isomerase Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100037528 ER membrane protein complex subunit 3 Human genes 0.000 description 4
- 241001492222 Epicoccum Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101000880977 Homo sapiens ER membrane protein complex subunit 3 Proteins 0.000 description 4
- 101100389281 Mus musculus Emc3 gene Proteins 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- 206010038923 Retinopathy Diseases 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 206010008027 Cerebellar atrophy Diseases 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- 241001101998 Galium Species 0.000 description 2
- 235000014820 Galium aparine Nutrition 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057267 Periphlebitis Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003198 cerebellar cortex Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000003636 hereditary ataxia Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000032646 lung growth Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000001213 vestibule labyrinth Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910397466.2A CN110100788B (zh) | 2019-05-14 | 2019-05-14 | 基于基因操作策略构建疾病模型的方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910397466.2A CN110100788B (zh) | 2019-05-14 | 2019-05-14 | 基于基因操作策略构建疾病模型的方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110100788A true CN110100788A (zh) | 2019-08-09 |
CN110100788B CN110100788B (zh) | 2021-07-16 |
Family
ID=67489868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910397466.2A Active CN110100788B (zh) | 2019-05-14 | 2019-05-14 | 基于基因操作策略构建疾病模型的方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110100788B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110463663A (zh) * | 2019-08-27 | 2019-11-19 | 四川大学华西医院 | 一种视网膜血管瘤样增生和/或视网膜毛细血管瘤模型构建方法 |
CN110607280A (zh) * | 2019-08-28 | 2019-12-24 | 华中农业大学 | Emc3基因的应用及其定点敲除方法 |
CN111485003A (zh) * | 2020-05-06 | 2020-08-04 | 四川省人民医院 | 一种视网膜血管疾病模型的构建方法及其应用 |
CN111500638A (zh) * | 2019-12-20 | 2020-08-07 | 四川省人民医院 | 利用基因操作技术构建视网膜新生血管疾病动物模型的方法、培育方法和应用 |
CN113957074A (zh) * | 2021-10-25 | 2022-01-21 | 电子科技大学 | 一种小脑共济失调疾病模型的构建方法及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104017818A (zh) * | 2014-06-24 | 2014-09-03 | 中山大学 | 亚细胞定位的炎症小体活性报告系统及其应用 |
CN107164406A (zh) * | 2017-05-25 | 2017-09-15 | 朱献军 | 胰岛β细胞条件性敲除Tmem30a基因小鼠模型的构建方法及应用 |
CN107586791A (zh) * | 2017-10-26 | 2018-01-16 | 四川省人民医院 | 一种共济失调动物模型的构建方法以及应用 |
CN108467873A (zh) * | 2017-03-17 | 2018-08-31 | 北京百奥赛图基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
CN109182355A (zh) * | 2018-09-17 | 2019-01-11 | 四川省人民医院 | 视网膜新生血管疾病模型的构建方法和应用 |
WO2019090020A1 (en) * | 2017-11-02 | 2019-05-09 | University Of Georgia Research Foundation, Inc. | Methods and compositions related to increased rotavirus production |
CN110381976A (zh) * | 2016-12-05 | 2019-10-25 | 努里塔斯有限公司 | 包括肽wkdeagkplvk的组合物 |
-
2019
- 2019-05-14 CN CN201910397466.2A patent/CN110100788B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104017818A (zh) * | 2014-06-24 | 2014-09-03 | 中山大学 | 亚细胞定位的炎症小体活性报告系统及其应用 |
CN110381976A (zh) * | 2016-12-05 | 2019-10-25 | 努里塔斯有限公司 | 包括肽wkdeagkplvk的组合物 |
CN108467873A (zh) * | 2017-03-17 | 2018-08-31 | 北京百奥赛图基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
CN107164406A (zh) * | 2017-05-25 | 2017-09-15 | 朱献军 | 胰岛β细胞条件性敲除Tmem30a基因小鼠模型的构建方法及应用 |
CN107586791A (zh) * | 2017-10-26 | 2018-01-16 | 四川省人民医院 | 一种共济失调动物模型的构建方法以及应用 |
WO2019090020A1 (en) * | 2017-11-02 | 2019-05-09 | University Of Georgia Research Foundation, Inc. | Methods and compositions related to increased rotavirus production |
CN109182355A (zh) * | 2018-09-17 | 2019-01-11 | 四川省人民医院 | 视网膜新生血管疾病模型的构建方法和应用 |
Non-Patent Citations (3)
Title |
---|
余曾洋等: "氧诱导新生小鼠视网膜病变中血管新生和氧应激相关基因表达的变化", 《中国药理学通报》 * |
刘玉庆等: "家族性渗出性玻璃体视网膜病变患者LRP5基因突变研究", 《遗传HEREDITAS(BEIJING)》 * |
朱献军: "尿酸氧化酶基因的克隆、表达及其产物的应用", 《生物工程学报》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110463663A (zh) * | 2019-08-27 | 2019-11-19 | 四川大学华西医院 | 一种视网膜血管瘤样增生和/或视网膜毛细血管瘤模型构建方法 |
CN110463663B (zh) * | 2019-08-27 | 2021-09-17 | 四川大学华西医院 | 一种视网膜血管瘤样增生和/或视网膜毛细血管瘤模型构建方法 |
CN110607280A (zh) * | 2019-08-28 | 2019-12-24 | 华中农业大学 | Emc3基因的应用及其定点敲除方法 |
CN111500638A (zh) * | 2019-12-20 | 2020-08-07 | 四川省人民医院 | 利用基因操作技术构建视网膜新生血管疾病动物模型的方法、培育方法和应用 |
CN111500638B (zh) * | 2019-12-20 | 2021-11-05 | 四川省人民医院 | 利用基因操作技术构建视网膜新生血管疾病动物模型的方法、培育方法和应用 |
CN111485003A (zh) * | 2020-05-06 | 2020-08-04 | 四川省人民医院 | 一种视网膜血管疾病模型的构建方法及其应用 |
CN113957074A (zh) * | 2021-10-25 | 2022-01-21 | 电子科技大学 | 一种小脑共济失调疾病模型的构建方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110100788B (zh) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110100788A (zh) | 基于基因操作策略构建疾病模型的方法和应用 | |
Nakayama et al. | Xenopus pax6 mutants affect eye development and other organ systems, and have phenotypic similarities to human aniridia patients | |
CN108486152A (zh) | 转基因猪的培育方法和应用 | |
CN107206105A (zh) | 色素性视网膜炎的rpgr基因疗法 | |
CN109674819A (zh) | 胎盘间充质干细胞制剂及其治疗硬化病的用途 | |
CN105112448A (zh) | Stch基因敲除动物模型的构建方法及应用 | |
Baffet et al. | Cellular and subcellular imaging of motor protein-based behavior in embryonic rat brain | |
CN109646458A (zh) | 使用胎盘间充质干细胞制剂治疗硬化病的方法 | |
Song et al. | Development of the nude rabbit model | |
CN116898970A (zh) | Atp5d激活剂与b淋巴细胞在制备药物中的用途 | |
US11653636B2 (en) | Method of making a rat model of retinal degeneration and rat model made thereby | |
Praet et al. | Histological characterization and quantification of cellular events following neural and fibroblast (-like) stem cell grafting in healthy and demyelinated CNS tissue | |
KR102177174B1 (ko) | Pde6b 유전자가 결손된 망막 변성 동물 모델 및 이의 제조 방법 | |
CN112574943A (zh) | 一种体外模拟皮肤癣菌感染的模型及其建立方法和应用 | |
Liu et al. | Characterization and allogeneic transplantation of a novel transgenic cone-rich donor mouse line | |
Adler et al. | Comparison of proteins in the interphotoreceptor matrix of vertebrates | |
US20210205360A1 (en) | Methods and compositions for the treatment of osteopetrosis | |
Maes et al. | Mitochondrial network adaptations of microglia reveal sex-specific stress response after injury and UCP2 knockout | |
CN114934113B (zh) | Alpk1基因在白内障诊断治疗及构建动物模型中的应用 | |
Qiu et al. | ASD mutation of Katnal2 impairs ependymal ciliary motion and causes hydrocephalus | |
CN109112134A (zh) | 一种视网膜变性疾病的best1新突变致病基因及其试剂盒 | |
KR20200110557A (ko) | 유방암 동물모델의 제조방법 및 이의 용도 | |
CN110755427A (zh) | 一种治疗视网膜退行性疾病的药物 | |
CN108969539A (zh) | 宫内膜干细胞在制备用于预防或治疗肺纤维化药物的应用 | |
CN113862346B (zh) | 长链非编码rna在治疗阿尔茨海默病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191016 Address after: 610000, No. 2, section 32, West Ring Road, Qingyang District, Sichuan, Chengdu Applicant after: SICHUAN PROVINCIAL PEOPLE'S HOSPITAL AFFILIATED HOSPITAL OF University OF ELECTRONIC SCIENCE AND TECHNOLOGY Address before: 610000, No. 2, section 32, West Ring Road, Qingyang District, Sichuan, Chengdu Applicant before: SICHUAN PROVINCIAL PEOPLE'S HOSPITAL |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.32, Section 2, West 1st ring road, Qingyang District, Chengdu, Sichuan 610000 Patentee after: Sichuan Academy of Medical Sciences. Sichuan people's Hospital Address before: No.32, Section 2, West 1st ring road, Qingyang District, Chengdu, Sichuan 610000 Patentee before: SICHUAN PROVINCIAL PEOPLE'S HOSPITAL AFFILIATED HOSPITAL OF University OF ELECTRONIC SCIENCE AND TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230825 Address after: B1/2/3, D1, No. 7-4 Hexin Road, Lianhuashan Industrial Park, Jiangshan Economic Development Zone, Jiangshan City, Quzhou City, Zhejiang Province, 324100 Patentee after: ZHEJIANG DINGYI BIOLOGICAL TECHNOLOGY CO.,LTD. Address before: No.32, Section 2, West 1st ring road, Qingyang District, Chengdu, Sichuan 610000 Patentee before: Sichuan Academy of Medical Sciences. Sichuan people's Hospital |